These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9403933)

  • 1. Decrease in viral load associated with topical dinitrochlorobenzene therapy in HIV disease.
    Stricker RB; Goldberg B; Mills LB; Epstein WL
    Res Virol; 1997; 148(5):343-8. PubMed ID: 9403933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical immune modulation with dinitrochlorobenzene in HIV disease: a controlled trial from Brazil.
    Traub A; Margulis SB; Stricker RB
    Dermatology; 1997; 195(4):369-73. PubMed ID: 9529559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot study of topical dinitrochlorobenzene (DNCB) in human immunodeficiency virus infection.
    Stricker RB; Zhu YS; Elswood BF; Dumlao C; Van Elk J; Berger TG; Tappero J; Epstein WL; Kiprov DD
    Immunol Lett; 1993 Apr; 36(1):1-6. PubMed ID: 8102123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased soluble Fas in HIV-infected hemophilia patients with CD4+ and CD8+ cell count increases and viral load and immune complex decreases.
    Daniel V; Süsal C; Weimer R; Zimmermann R; Huth-Kühne A; Opelz G
    AIDS Res Hum Retroviruses; 2001 Mar; 17(4):329-35. PubMed ID: 11242519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
    García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
    AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy.
    Bouscarat F; Levacher M; Landman R; Muffat-Joly M; Girard PM; Saimot AG; Brun-Vézinet F; Sinet M
    AIDS; 1998 Jul; 12(11):1267-73. PubMed ID: 9708405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.
    Kaufmann GR; Bloch M; Zaunders JJ; Smith D; Cooper DA
    AIDS; 2000 May; 14(8):959-69. PubMed ID: 10853977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined antiviral therapy reduces HIV-1 plasma load and improves CD4 counts but does not interfere with ongoing lymphocyte apoptosis.
    Moretti S; Alesse E; Marcellini S; Di Marzio L; Zazzeroni F; Parroni R; Famularo G; Boschini A; Cifone MG; De Simone C
    Immunopharmacol Immunotoxicol; 1999 Nov; 21(4):645-65. PubMed ID: 10584202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.
    Schapiro JM; Winters MA; Stewart F; Efron B; Norris J; Kozal MJ; Merigan TC
    Ann Intern Med; 1996 Jun; 124(12):1039-50. PubMed ID: 8633817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
    García F; Plana M; Vidal C; Cruceta A; O'Brien WA; Pantaleo G; Pumarola T; Gallart T; Miró JM; Gatell JM
    AIDS; 1999 Jul; 13(11):F79-86. PubMed ID: 10449278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved results of delayed-type hypersensitivity skin testing in HIV-infected patients treated with topical dinitrochlorobenzene.
    Stricker RB; Goldberg B; Mills LB; Epstein WL
    J Am Acad Dermatol; 1995 Oct; 33(4):608-11. PubMed ID: 7673493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.
    Price DA; Scullard G; Oxenius A; Braganza R; Beddows SA; Kazmi S; Clarke JR; Johnson GE; Weber JN; Phillips RE
    J Virol; 2003 May; 77(10):6041-9. PubMed ID: 12719595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial.
    Davey RT; Murphy RL; Graziano FM; Boswell SL; Pavia AT; Cancio M; Nadler JP; Chaitt DG; Dewar RL; Sahner DK; Duliege AM; Capra WB; Leong WP; Giedlin MA; Lane HC; Kahn JO
    JAMA; 2000 Jul; 284(2):183-9. PubMed ID: 10889591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and immunologic evaluation of HIV-infected patients treated with dinitrochlorobenzene.
    Stricker RB; Elswood BF; Goldberg B; Dumlao C; Van Elk J; Henry J; Winger EE; Epstein WL
    J Am Acad Dermatol; 1994 Sep; 31(3 Pt 1):462-6. PubMed ID: 8077474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.
    Sölder B; Wintergerst U; Notheis G; Eberle J; Gürtler L; Belohradsky BH
    J Pediatr; 1997 Feb; 130(2):293-9. PubMed ID: 9042135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
    Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
    JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
    Gray CM; Schapiro JM; Winters MA; Merigan TC
    AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.